Our lead program is a gene editing therapy, MyoDys45-55, for Duchenne muscular dystrophy (DMD), a devastating muscle wasting disease. MyoGene Bio utilizes new technologies to have a strong positive effect on disease progression by targeting the underlying cause of disease. Our company philosophy is to make meaningful impacts on muscle diseases through our dedication to honesty, integrity, and innovation.
Our Team
Our team is a dedicated group of scientists with over 50 cumulative years of experience in research and treatment of muscle diseases. We are experienced in innovative research, creating and managing biomedical research laboratories, and in the conduct of clinical trials.